How to buy Avadel Pharmaceuticals stock (AVDL)

Avadel Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Avadel Pharmaceuticals shares (AVDL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $10.33 – a decrease of 2.64% over the previous week. Avadel Pharmaceuticals employs 154 staff and has a trailing 12-month revenue of around $95.1 million.

Our top picks for where to buy Avadel Pharmaceuticals stock

Buy Avadel Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Avadel Pharmaceuticals stock price (NASDAQ: AVDL)

Use our graph to track the performance of AVDL stocks over time.

Avadel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-15.

Latest market close	$10.33
52-week range	$9.41 - $19.09
50-day moving average more info button	$13.67
200-day moving average more info button	$15.28
Wall St. target price	$24.70
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.09

Is it a good time to buy Avadel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avadel Pharmaceuticals price performance over time

Historical closes compared with the close of $10.73 from 2024-12-17

1 week (2024-12-12)	1.13%
1 month (2024-11-20)	-0.19%
3 months (2024-09-19)	-21.10%
6 months (2024-06-18)	-31.22%

1 year (2023-12-19)	-24.44%
2 years (2022-12-19)	57.10%
3 years (2021-12-17)	42.69%
5 years (2019-12-19)	70.59%

Is Avadel Pharmaceuticals stock undervalued or overvalued?

Valuing Avadel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avadel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Avadel Pharmaceuticals's PEG ratio

Avadel Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Avadel Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Avadel Pharmaceuticals financials

Revenue TTM	$95.1 million
Gross profit TTM	$16.6 million
Return on assets TTM	-34.45%
Return on equity TTM	-99.52%
Profit margin	-111.64%
Book value	$0.98
Market Capitalization more info button	$1.3 billion

TTM: trailing 12 months

Avadel Pharmaceuticals share dividends

We're not expecting Avadel Pharmaceuticals to pay a dividend over the next 12 months.

Avadel Pharmaceuticals share price volatility

Over the last 12 months, Avadel Pharmaceuticals's shares have ranged in value from as little as $9.41 up to $19.09. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avadel Pharmaceuticals's is 1.632. This would suggest that Avadel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Avadel Pharmaceuticals overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. .

Frequently asked questions

null
What percentage of Avadel Pharmaceuticals is owned by insiders or institutions?
Currently 4.774% of Avadel Pharmaceuticals shares are held by insiders and 80.004% by institutions. How many people work for Avadel Pharmaceuticals?
Latest data suggests 154 work at Avadel Pharmaceuticals. When does the fiscal year end for Avadel Pharmaceuticals?
Avadel Pharmaceuticals's fiscal year ends in December. Where is Avadel Pharmaceuticals based?
Avadel Pharmaceuticals's address is: 10 Earlsfort Terrace, Dublin, Ireland, 2 What is Avadel Pharmaceuticals's ISIN number?
Avadel Pharmaceuticals's international securities identification number is: US05337M1045 What is Avadel Pharmaceuticals's CUSIP number?
Avadel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 338488109